Investor Overview

We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules.

In March 2012, we launched Subsys® , our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in adult opioid-tolerant patients, through our cost-efficient commercial organization of approximately 250 sales professionals.

Since late 2014, Subsys® has been the most prescribed transmucosal immediate-release fentanyl, or TIRF, product with 48% market share on a prescription basis, according to IMS.

In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company.

Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market Dronabinol Oral Solution and any other future supportive care products, if approved, through our commercial organization.

Please see full prescribing information for Subsys® including the boxed warning.

 

Recent News

Jul 20 2017
Insys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017
PHOENIX, July 20, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its second quarter 2017 financial results on Thursday, August 3, 2017, before the U.S. financial markets open... 
Jul 18 2017
Insys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer
PHOENIX, July 18, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) announced today that Andrew G. Long has joined the company as Chief Financial Officer, effective August 7, 2017. Andrew G. Long is a seasoned financ... 
Jul 17 2017
Insys Therapeutics, Inc. Releases Statement on Payor Interactions
PHOENIX, July 17, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) issued a statement today on its interactions with payors: Insys, in concert with its business partners, is dedicated to helping patients navigate the ... 
see all news

Receive Email Alerts

Sign Up Now

Upcoming Events

Q2 2017 Insys Therapeutics Inc Earnings Conference Call


Thursday, August 3, 2017 8:30 a.m. ET

see all events